Emergence of a SARS-CoV-2 E484K variant of interest in Arizona

Peter T. Skidmore; Emily A. Kaelin; LaRinda A. Holland; Rabia Maqsood; Lily I. Wu; Nicholas J. Mellor; Joy M. Blain; Valerie Harris; Joshua LaBaer; Vel Murugan; Efrem S. Lim

doi:10.1101/2021.03.26.21254367

Emergence of a SARS-CoV-2 E484K variant of interest in Arizona

Peter T. Skidmore, Emily A. Kaelin, LaRinda A. Holland, Rabia Maqsood, Lily I. Wu, Nicholas J. Mellor, Joy M. Blain, Valerie Harris, Joshua LaBaer, Vel Murugan, Efrem S. Lim

2021 · doi:10.1101/2021.03.26.21254367

preprint OA: gold CC-BY-NC-ND-4.0

📄 Open PDF View at publisher

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies via crossref
Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York via crossref
Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco via crossref
Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment via crossref
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants via crossref
Recurrent Emergence and Transmission of a SARS-CoV-2 Spike Deletion H69/V70 via crossref
The N501Y spike substitution enhances SARS-CoV-2 transmission via crossref
doi:10.1016/j.cell.2021.03.013 via crossref
doi:10.1016/j.cell.2021.02.042 via crossref
doi:10.3390/ijms22041695 via crossref
doi:10.1038/s41591-020-1092-0 via crossref
doi:10.1126/science.abd9338 via crossref
doi:10.1128/jvi.00711-20 via crossref
doi:10.1186/s13059-018-1618-7 via crossref
doi:10.1093/nar/gkf436 via crossref
doi:10.1002/gch2.1018 via crossref
doi:10.1093/molbev/msaa015 via crossref
doi:10.21105/joss.02906 via crossref
doi:10.1038/s41591-021-01270-4 via crossref
doi:10.1016/j.cell.2020.08.012 via crossref
doi:10.1136/bmj.n579 via crossref
doi:10.3201/eid2705.210191 via crossref
doi:10.1016/j.chom.2021.01.014 via crossref
doi:10.1016/j.chom.2021.02.003 via crossref

Source provenance

crossref: last seen: 2026-06-02T01:00:33.062255+00:00
europepmc: last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall: last seen: 2026-05-21T02:00:01.467718+00:00

License: CC-BY-NC-ND-4.0

[1] E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies via crossref

[2] Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York via crossref

[3] Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco via crossref

[4] Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment via crossref

[5] mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants via crossref

[6] Recurrent Emergence and Transmission of a SARS-CoV-2 Spike Deletion H69/V70 via crossref

[7] The N501Y spike substitution enhances SARS-CoV-2 transmission via crossref

[8] doi:10.1016/j.cell.2021.03.013 via crossref

[9] doi:10.1016/j.cell.2021.02.042 via crossref

[10] doi:10.3390/ijms22041695 via crossref

[11] doi:10.1038/s41591-020-1092-0 via crossref

[12] doi:10.1126/science.abd9338 via crossref

[13] doi:10.1128/jvi.00711-20 via crossref

[14] doi:10.1186/s13059-018-1618-7 via crossref

[15] doi:10.1093/nar/gkf436 via crossref

[16] doi:10.1002/gch2.1018 via crossref

[17] doi:10.1093/molbev/msaa015 via crossref

[18] doi:10.21105/joss.02906 via crossref

[19] doi:10.1038/s41591-021-01270-4 via crossref

[20] doi:10.1016/j.cell.2020.08.012 via crossref

[21] doi:10.1136/bmj.n579 via crossref

[22] doi:10.3201/eid2705.210191 via crossref

[23] doi:10.1016/j.chom.2021.01.014 via crossref

[24] doi:10.1016/j.chom.2021.02.003 via crossref